Noncompaction cardiomyopathy medical therapy: Difference between revisions
No edit summary |
|||
| Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
The management of | The medical management of noncompaction cardiomyopathy is similar to that of other cardiomyopathies and includes the use of [[angiotensin-converting enzyme|ACE inhibitors]], [[Beta blocker|beta blockers]] and [[aspirin]]. | ||
==Antiplatelet Therapy== | ==Antiplatelet Therapy== | ||
| Line 9: | Line 9: | ||
==Beta Blockade== | ==Beta Blockade== | ||
Noncompaction cardiomyopathy is assocatiated with an increased risk of arrhythmias including ventricular tachyarrhythmias. Beta blockade may reduce this risk. | |||
==References== | ==References== | ||
Revision as of 11:14, 6 August 2011
|
Noncompaction Cardiomyopathy Microchapters |
|
Pathophysiology |
|---|
|
Differentiating Noncompaction Cardiomyopathy from other Diseases |
|
Diagnosis |
|
Treatment |
|
Noncompaction cardiomyopathy medical therapy On the Web |
|
Risk calculators and risk factors for Noncompaction cardiomyopathy medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The medical management of noncompaction cardiomyopathy is similar to that of other cardiomyopathies and includes the use of ACE inhibitors, beta blockers and aspirin.
Antiplatelet Therapy
Given the risk of embolization, these patients are generally treated with prophylactic aspirin.
Beta Blockade
Noncompaction cardiomyopathy is assocatiated with an increased risk of arrhythmias including ventricular tachyarrhythmias. Beta blockade may reduce this risk.